Back |
home / stock / nrsn / nrsn message board
Subject | By | Source | When |
---|---|---|---|
$NRSN: Let's break that $8 | Sibware | investorshub | 03/23/2022 1:48:26 PM |
,,,,,,,,WRONG | THEMASTERS_SON | investorshub | 03/23/2022 2:37:43 AM |
,,,,,,,BOOM! $6.30sTALENT ON LOAN FROM.GOD! | THEMASTERS_SON | investorshub | 03/22/2022 8:41:26 PM |
WE GREEN$ | THEMASTERS_SON | investorshub | 03/22/2022 8:15:50 PM |
,,,,,,SQUEEEEEEEEEEZE SEND THEM TO $12/GATES..OFHELL | THEMASTERS_SON | investorshub | 03/22/2022 5:32:40 PM |
$5 re-break!! | TheFinalCD | investorshub | 03/22/2022 5:03:54 PM |
5M FLOAT..ON LOCK!! WEEEEE | THEMASTERS_SON | investorshub | 03/22/2022 3:01:58 PM |
,,,,,,THANKS UP $20K BUYING DIP EOM | THEMASTERS_SON | investorshub | 03/22/2022 2:37:34 PM |
LETS GO TEN $$ | THEMASTERS_SON | investorshub | 03/22/2022 10:25:28 AM |
5M FLOAT = LGV* | THEMASTERS_SON | investorshub | 03/22/2022 4:47:10 AM |
,,,,,,,ITS REALLY HAPPENING CURE ALS | THEMASTERS_SON | investorshub | 03/22/2022 1:15:23 AM |
BAIT? lol | TheFinalCD | investorshub | 03/22/2022 12:24:16 AM |
$NRSN Chart | conix | investorshub | 03/21/2022 11:17:07 PM |
,,,,,,,IF LGV$& $CAN GO>>$45 WHYNOT US!!!! | THEMASTERS_SON | investorshub | 03/21/2022 10:39:57 PM |
Yep!! As I noted, pure 'SUCKERS BATE' right | Just-Keep-Trying | investorshub | 03/21/2022 9:30:37 PM |
And all because the SEC, OTC, & FBI | Just-Keep-Trying | investorshub | 03/21/2022 9:25:19 PM |
Yep! | Just-Keep-Trying | investorshub | 03/21/2022 9:23:02 PM |
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...